News Blow for AstraZeneca as cancer combination fails After several years of growing expectation, AstraZeneca’s long-awaited MYSTIC immune-oncology trial has failed to show benefit over standard lung cancer therapy.
News Soriot commits to AstraZeneca as shares slide AstraZeneca (AZ) has tried to put a brave face on today’s news that its immunotherapy combination is unlikely to be a contender in lung cancer.
News Medical chatbot firm OpenEvidence raises $210m OpenEvidence has raised $210m to expand the capabilities of its physician decision-making tool and launch a new service offering 'PhD-level' research.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face